Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 17/20 | 0.49 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HSD3B2 | P26439 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873080 | 0.74 | HSD11B1 (0.49) | HSD11B1CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL4083045 | 0.74 | HSD11B1 (0.49) | HSD11B1CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL1828050 | 0.73 | MAPT (0.36) | PLA2G7 | |
| SCHEMBL4082787 | 0.70 | HSD11B1 (0.44) | HSD11B1ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4094121 | 0.70 | HSD11B1 (0.48) | HSD11B1CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL10306123 | 0.69 | KMT2A (0.47) | HSD11B1ALDH1A1KMT2A | |
| SCHEMBL4088740 | 0.67 | HSD11B1 (0.48) | HSD11B1ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8023232 | 0.67 | PSEN1 (0.49) | HSD11B1CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL12685149 | 0.66 | HSD11B1 (0.54) | HSD11B1 | |
| SCHEMBL3715276 | 0.66 | HSD11B1 (0.54) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2019094-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | CLIC4, NR3C2, MAN2B1 | HSD11B1 194/4885PLA2G7 2421/4885ALDH1A1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.